UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
| (Mark One) | ||
| x |
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended September 27, 2003
or
| o |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to
Commission file number: 0-27892
SIPEX Corporation
(Exact Name of Registrant as Specified in its Charter)
| Delaware (State or Other Jurisdiction of Incorporation or Organization) |
04-6135748 (I.R.S. Employer Identification No.) |
|
| 233 South Hillview Drive, Milpitas, California (Address of principal executive offices) |
95035 (Zip Code) |
(408) 934-7500
Registrants telephone number, including area code
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o
Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Act). Yes x No o
There were 28,257,100 shares of the Registrants Common Stock issued and outstanding as of November 7, 2003.
FORM 10-Q
NINE MONTHS ENDED SEPTEMBER 27, 2003
INDEX
| Item | ||||||||
| Number | Page | |||||||
| PART I: | FINANCIAL INFORMATION | |||||||
| Item 1. | Financial Statement | |||||||
| Consolidated Balance Sheets at September 27, 2003 and December 31, 2002 | 3 | |||||||
| Consolidated Statements of Operations for the three and nine months ended September 27, 2003 and September 28, 2002 | 4 | |||||||
| Consolidated Statements of Cash Flows for the nine months ended September 27, 2003 and September 28, 2002 | 5 | |||||||
| Notes To Consolidated Financial Statements | 6 | |||||||
| Item 2. | Managements Discussion and Analysis of Financial Condition and Results of Operations | 13 | ||||||
| Item 3. | Quantitative and Qualitative Disclosure about Market Risk | 29 | ||||||
| Item 4. | Controls and Procedures | 30 | ||||||
| PART II: | OTHER INFORMATION | |||||||
| Item 1. | Legal Proceedings | 31 | ||||||
| Item 2. | Changes in Securities and Use of Proceeds | 31 | ||||||
| Item 3. | Defaults Upon Senior Securities | 31 | ||||||
| Item 4. | Submission of Matters to a Vote of Security Holders | 31 | ||||||
| Item 5. | Other Information | 31 | ||||||
| Item 6. | Exhibits and Reports on Form 8-K | 31 | ||||||
| SIGNATURES | 32 | |||||||
2
Part I: FINANCIAL INFORMATION
Item 1: Financial Statements
SIPEX CORPORATION
CONSOLIDATED BALANCE SHEETS
(In thousands, except per share data)
(Unaudited)
| September 27, 2003 | December 31, 2002 | |||||||||
ASSETS |
||||||||||
Current assets: |
||||||||||
Cash and cash equivalents |
$ | 10,206 | $ | 6,489 | ||||||
Short-term investment securities |
6,486 | 9,980 | ||||||||
Accounts receivable, net |
8,058 | 7,278 | ||||||||
Accounts receivable, net, related party (note 3) |
3,069 | | ||||||||
Inventories, net |
15,094 | 14,393 | ||||||||
Prepaid expenses and other current assets |
2,543 | 3,446 | ||||||||
Total current assets |
45,456 | 41,586 | ||||||||
Property, plant, and equipment, net |
51,766 | 56,997 | ||||||||
Other assets |
456 | 203 | ||||||||
Total assets |
$ | 97,678 | $ | 98,786 | ||||||
LIABILITIES AND SHAREHOLDERS EQUITY |
||||||||||
Current liabilities: |
||||||||||
Accounts payable |
$ | 6,365 | $ | 8,103 | ||||||
Accrued expenses |
4,728 | 3,570 | ||||||||
Accrued restructuring costs |
| 755 | ||||||||
Deferred income, related party (note 3) |
4,006 | 1,383 | ||||||||
Total current liabilities |
15,099 | 13,811 | ||||||||
Long-term debt, related party (note 3) |
21,244 | 10,455 | ||||||||
Total liabilities |
36,343 | 24,266 | ||||||||
Commitments
(Note 9) |
| | ||||||||
Shareholders equity: Preferred stock, $0.01 par
value, 1,000 shares authorized and no shares
issued or outstanding |
| | ||||||||
Common stock, $0.01 par value, 60,000 shares
authorized; 28,216 and 28,031 shares issued and
outstanding at September 27, 2003 and December
31, 2002, respectively |
282 | 280 | ||||||||
Additional paid-in capital |
177,450 | 175,489 | ||||||||
Accumulated deficit |
(116,384 | ) | (101,179 | ) | ||||||
Accumulated other comprehensive loss |
(13 | ) | (70 | ) | ||||||
Total shareholders equity |
61,335 | 74,520 | ||||||||
Total liabilities and shareholders equity |
$ | 97,678 | $ | 98,786 | ||||||
See accompanying notes to consolidated financial statements
3
SIPEX CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data)
(Unaudited)
| Three Months Ended | Nine Months Ended | |||||||||||||||||||
| September 27, | September 28, | September 27, | September 28, | |||||||||||||||||
| 2003 | 2002 | 2003 | 2002 | |||||||||||||||||
Net sales |
$ | 10,462 | $ | 16,625 | $ | 31,273 | $ | 49,677 | ||||||||||||
Net
sales, related party (note 3) |
5,950 | | 15,146 | | ||||||||||||||||
Net sales, before fair value of debt conversion rights |
16,412 | 16,625 | 46,419 | 49,677 | ||||||||||||||||
Fair value of debt conversion rights, related party (note 3) |
(1,214 | ) | | (1,214 | ) | | ||||||||||||||
Total net sales |
15,198 | 16,625 | 45,205 | 49,677 | ||||||||||||||||
Cost of sales |
7,881 | 21,272 | 27,215 | 54,092 | ||||||||||||||||
Cost of sales, related party (note 3) |
3,748 | | 12,246 | | ||||||||||||||||
Restructuring costs |
| 1,909 | (37 | ) | 1,909 | |||||||||||||||
Total cost of sales |
11,629 | 23,181 | 39,424 | 56,001 | ||||||||||||||||
Gross profit (loss) |
3,569 | (6,556 | ) | 5,781 | (6,324 | ) | ||||||||||||||
Operating expenses: |
||||||||||||||||||||
Research and development |
3,377 | 3,407 | 9,738 | 9,680 | ||||||||||||||||
Marketing and selling |
1,759 | 1,813 | 5,126 | 6,286 | ||||||||||||||||
General and administrative |
1,563 | 1,816 | 5,679 | 6,116 | ||||||||||||||||
Reorganization |
| 1,623 | | 1,623 | ||||||||||||||||
Restructuring and facility exit costs |
(29 | ) | 3,806 | (329 | ) | 3,806 | ||||||||||||||
Impairment charges |
| 1,819 | | 1,819 | ||||||||||||||||
Impairment of goodwill |
| | | 2,984 | ||||||||||||||||
Total operating expenses |
6,670 | 14,284 | 20,214 | 32,314 | ||||||||||||||||
Loss from operations |
(3,101 | ) | (20,840 | ) | (14,433 | ) | (38,638 | ) | ||||||||||||
Interest income |
31 | 45 | 96 | 120 | ||||||||||||||||
Interest expense |
(216 | ) | | (556 | ) | (81 | ) | |||||||||||||
Other expense, net |
(32 | ) | (102 | ) | (21 | ) | (813 | ) | ||||||||||||
Total other expense, net |
(217 | ) | (57 | ) | (481 | ) | (774 | ) | ||||||||||||
Loss before income taxes |
(3,318 | ) | (20,897 | ) | (14,914 | ) | (39,412 | ) | ||||||||||||
Income tax expense |
27 | 178 | 291 | 32,113 | ||||||||||||||||
Net loss |
$ | (3,345 | ) | $ | (21,075 | ) | $ | (15,205 | ) | $ | (71,525 | ) | ||||||||
Net loss per common share basic and diluted |
$ | (0.12 | ) | $ | (0.75 | ) | $ | (0.54 | ) | $ | (2.66 | ) | ||||||||
Weighted average common shares outstanding basic and diluted |
28,145 | 27,955 | 28,077 | 26,920 | ||||||||||||||||
See accompanying notes to consolidated financial statements
4
SIPEX CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
(Unaudited)
| Nine Months Ended | ||||||||||||
| September 27, | September 28, | |||||||||||
| 2003 | 2002 | |||||||||||
Operating activities: |
||||||||||||
Net loss |
$ | (15,205 | ) | $ | (71,525 | ) | ||||||
Adjustments to reconcile net loss to net cash used in operating activities: |
||||||||||||
Fair
value of debt conversion rights (note 3) |
1,214 | | ||||||||||
Deferred income taxes |
| 31,851 | ||||||||||
Provision (reversal) for uncollectible receivables and returns and allowances |
(604 | ) | 1,890 | |||||||||
Fixed asset impairment loss |
649 | | ||||||||||
Stock compensation expense |
56 | | ||||||||||
(Gain) loss on fixed asset disposition |
196 | (123 | ) | |||||||||
Depreciation and amortization |
5,799 | 9,160 | ||||||||||
Impairment charges |
| 1,819 | ||||||||||
Restructuring and reorganization charges |
| 7,338 | ||||||||||
Amortization of discount on long-term debt, related party (note 3) |
242 | | ||||||||||
Changes in current assets and liabilities: |
||||||||||||
Accounts receivable |
(3,245 | ) | (837 | ) | ||||||||
Inventories, net |
(701 | ) | 3,732 | |||||||||
Prepaid expenses and other current assets |
903 | (142 | ) | |||||||||
Other assets |
(138 | ) | | |||||||||
Accounts payable |
(1,738 | ) | 4,961 | |||||||||
Accrued expenses |
1,158 | 1,180 | ||||||||||
Accrued restructuring costs |
(755 | ) | | |||||||||
Deferred income, related party (note 3) |
2,623 | 100 | ||||||||||
Net cash used in operating activities |
(9,546 | ) | (10,596 | ) | ||||||||
Investing activities: |
||||||||||||
Purchase of short-term investment securities |
(7,469 | ) | | |||||||||
Proceeds from maturity of short-term investment securities |
10,963 | (5,994 | ) | |||||||||
Purchase of property, plant and equipment |
(1,413 | ) | (3,569 | ) | ||||||||
Net cash provided by (used in) investing activities |
2,081 | (9,563 | ) | |||||||||
Financing activities: |
||||||||||||
Debt issuance costs |
(128 | ) | | |||||||||
Proceeds from issuance of common stock |
694 | 24,226 | ||||||||||
Proceeds from issuance of convertible secured notes, related party (note 3) |
10,560 | 12,000 | ||||||||||
Payments of debt obligations |
| (7,396 | ) | |||||||||
Net cash provided by financing activities |
11,125 | 28,830 | ||||||||||
Effect of foreign currency exchange rate changes on cash and cash equivalents |
57 | (61 | ) | |||||||||
Increase in cash and cash equivalents |
3,717 | 8,610 | ||||||||||
Cash and cash equivalents, beginning of period |
6,489 | 4,874 | ||||||||||
Cash and cash equivalents, end of period |
$ | 10,206 | $ | 13,484 | ||||||||
Supplemental cash flow information: |
||||||||||||
Cash paid during the period for: |
||||||||||||
Income taxes |
$ | 143 | $ | 81 | ||||||||
Interest |
$ | | $ | 12 | ||||||||
See accompanying notes to consolidated financial statements
5
SIPEX CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Note 1. Basis of Presentation
Unaudited Interim Financial Information
We have prepared the accompanying consolidated financial statements pursuant to the rules and regulations of the Securities and Exchange Commission (the SEC) for interim financial reporting. As used herein, Sipex, the Company, we, our and similar terms include Sipex Corporation and its wholly-owned subsidiaries, unless the context indicates otherwise. These consolidated financial statements are unaudited and, in our opinion, include all adjustments, consisting of normal recurring adjustments and accruals necessary for a fair presentation of the consolidated balance sheets, operating results and cash flows for the periods presented. Operating results for the three and nine months ended September 27, 2003 are not necessarily indicative of the results that may be expected for the year ending December 31, 2003 due to cyclical and other factors. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been omitted in accordance with the rules and regulations of the SEC. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2002. Certain prior period amounts have been reclassified to conform to the current period presentation. Such reclassifications had no effect on net loss as previously reported.
Principles of Consolidation
The consolidated financial statements include the accounts of Sipex and all of its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.
Stock-Based Compensation
In December 2002, the FASB issued SFAS No. 148, Accounting for Stock-Based Compensation Transition and Disclosure an Amendment of SFAS 123. SFAS No. 148 provides additional transition guidance for those entities that elect to voluntarily adopt the provisions of SFAS No. 123, Accounting for Stock-Based Compensation. Furthermore, SFAS No. 148 mandates prominent disclosures in both interim and year-end financial statements about the fair value based method of accounting for stock-based employee compensation and the effect of the method used on reported results. SFAS No. 148 is effective for fiscal years ending after December 15, 2002. The adoption of SFAS No. 148 did not have a material effect on the Companys financial position or results of operations as the Company does not intend to adopt the fair value method of accounting for stock-based employee compensation.
The Company accounts for its stock-based employee compensation plans under the recognition and measurement principles of APB Opinion No. 25, Accounting for Stock Issued to Employees, and related interpretations. The Company recorded $5,600 and $50,000 in stock based compensation, reflected in net loss for the three and nine months ended September 27, 2003, respectively. The Company principally grants employee stock options at exercise prices equal to the market value of the underlying common stock on the date of grant. The following table illustrates the effect on net loss and net loss per share as if the Company had applied the fair value recognition provisions of FASB Statement No. 123, Accounting for Stock Based Compensation, as amended by SFAS No. 148, to stock-based employee compensation in each period: (in thousands, except per share data)
| 3 Months Ended | 9 Months Ended | ||||||||||||||||
| September 27, | September 28, | September 27, | September 28, | ||||||||||||||
| 2003 | 2002 | 2003 | 2002 | ||||||||||||||
Net loss |
$ | 3,345 | $ | 21,075 | $ | 15,205 | $ | 71,525 | |||||||||
Less: Total stock-based employee
compensation expense determined
under fair value based method for
all awards, net of related tax
effects |
4,593 | 4,109 | 13,170 | 11,226 | |||||||||||||
Pro forma net loss |
7,938 | 25,184 | 28,375 | 82,751 | |||||||||||||
6
| 3 Months Ended | 9 Months Ended | ||||||||||||||||
| September 27, | September 28, | September 27, | September 28, | ||||||||||||||
| 2003 | 2002 | 2003 | 2002 | ||||||||||||||
Net loss per share: |
|||||||||||||||||